Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Elicio Therapeutics (ELTX) Consolidated Net Income (2020 - 2026)

Elicio Therapeutics filings provide 4 years of Consolidated Net Income readings, the most recent being -$9.3 million for Q4 2023.

  • On a quarterly basis, Consolidated Net Income fell 55.37% to -$9.3 million in Q4 2023 year-over-year; TTM through Dec 2023 was -$36.4 million, a 5.24% decrease, with the full-year FY2025 number at -$38.8 million, up 14.51% from a year prior.
  • Consolidated Net Income hit -$9.3 million in Q4 2023 for Elicio Therapeutics, up from -$10.5 million in the prior quarter.
  • In the past five years, Consolidated Net Income ranged from a high of $14.6 million in Q4 2021 to a low of -$19.9 million in Q1 2021.
  • Median Consolidated Net Income over the past 4 years was -$11.1 million (2020), compared with a mean of -$10.4 million.
  • Biggest five-year swings in Consolidated Net Income: skyrocketed 205.66% in 2021 and later crashed 140.99% in 2022.
  • Elicio Therapeutics' Consolidated Net Income stood at -$13.8 million in 2020, then skyrocketed by 205.66% to $14.6 million in 2021, then crashed by 140.99% to -$6.0 million in 2022, then tumbled by 55.37% to -$9.3 million in 2023.
  • The last three reported values for Consolidated Net Income were -$9.3 million (Q4 2023), -$10.5 million (Q3 2023), and -$8.5 million (Q2 2023) per Business Quant data.